The Acrylamide (S)-2 As a Positive and Negative Modulator of Kv7 Channels Expressed in Xenopus Laevis Oocytes

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2009 Dec 17

PMID 20011514

Citations 14

Authors

Sigrid Marie Blom

Nicole Schmitt

Henrik Sindal Jensen

Affiliations

Soon will be listed here.

Abstract

Background: Activation of voltage-gated potassium channels of the Kv7 (KCNQ) family reduces cellular excitability. These channels are therefore attractive targets for treatment of diseases characterized by hyperexcitability, such as epilepsy, migraine and neuropathic pain. Retigabine, which opens Kv7.2-5, is now in clinical trial phase III for the treatment of partial onset seizures. One of the main obstacles in developing Kv7 channel active drugs has been to identify compounds that can discriminate between the neuronal subtypes, a feature that could help diminish side effects and increase the potential of drugs for particular indications.

Methodology/principal Findings: In the present study we have made a thorough investigation of the Bristol-Myers Squibb compound (S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1], [4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide [(S)-2] on human Kv7.1-5 channels expressed in Xenopus laevis oocytes. We found that the compound was a weak inhibitor of Kv7.1. In contrast, (S)-2 efficiently opened Kv7.2-5 by producing hyperpolarizing shifts in the voltage-dependence of activation and enhancing the maximal current amplitude. Further, it reduced inactivation, accelerated activation kinetics and slowed deactivation kinetics. The mechanisms of action varied between the subtypes. The enhancing effects of (S)-2 were critically dependent on a tryptophan residue in S5 also known to be crucial for the effects of retigabine, (S)-1 and BMS-204352. However, while (S)-2 did not at all affect a mutant Kv7.4 with a leucine in this position (Kv7.4-W242L), a Kv7.2 with the same mutation (Kv7.2-W236L) was inhibited by the compound, showing that (S)-2 displays a subtype-selective interaction with in the Kv7 family.

Conclusions/significance: These results offer further insight into pharmacological activation of Kv7 channels, add to the understanding of small molecule interactions with the channels and may contribute to the design of subtype selective modulators.

Citing Articles

Voltage-gated potassium channels control extended access cocaine seeking: a role for nucleus accumbens astrocytes.

Xia M, Anderson T, Prantzalos E, Hawkinson T, Clarke H, Keohane S Neuropsychopharmacology. 2023; 49(3):551-560.

PMID: 37660129 PMC: 10789875. DOI: 10.1038/s41386-023-01718-w.

Behavior of KCNQ Channels in Neural Plasticity and Motor Disorders.

Singh S, William M, Malavia M, Chu X Membranes (Basel). 2022; 12(5).

PMID: 35629827 PMC: 9143857. DOI: 10.3390/membranes12050499.

Chemical modulation of Kv7 potassium channels.

Borgini M, Mondal P, Liu R, Wipf P RSC Med Chem. 2021; 12(4):483-537.

PMID: 34046626 PMC: 8128042. DOI: 10.1039/d0md00328j.

Pharmacological Activation of Neuronal Voltage-Gated Kv7/KCNQ/M-Channels for Potential Therapy of Epilepsy and Pain.

Liu Y, Bian X, Wang K Handb Exp Pharmacol. 2021; 267:231-251.

PMID: 33837465 DOI: 10.1007/164_2021_458.

The yin and yang of K channels in cerebral small vessel pathologies.

Koide M, Moshkforoush A, Tsoukias N, Hill-Eubanks D, Wellman G, Nelson M Microcirculation. 2017; 25(1).

PMID: 29247493 PMC: 5760473. DOI: 10.1111/micc.12436.

References

Tatulian L, Brown D . Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol. 2003; 549(Pt 1):57-63. PMC: 2342928. DOI: 10.1113/jphysiol.2003.039842. View

Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch T, Grotzinger J . Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci. 2005; 25(20):5051-60. PMC: 6724866. DOI: 10.1523/JNEUROSCI.0128-05.2005. View

Wickenden A, Yu W, Zou A, Jegla T, Wagoner P . Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000; 58(3):591-600. DOI: 10.1124/mol.58.3.591. View

Xiong Q, Sun H, Li M . Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007; 3(5):287-96. DOI: 10.1038/nchembio874. View

Kharkovets T, Hardelin J, Safieddine S, Schweizer M, El-Amraoui A, Petit C . KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci U S A. 2000; 97(8):4333-8. PMC: 18242. DOI: 10.1073/pnas.97.8.4333. View

Wuttke T, Seebohm G, Bail S, Maljevic S, Lerche H . The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005; 67(4):1009-17. DOI: 10.1124/mol.104.010793. View

Seebohm G, Strutz-Seebohm N, Baltaev R, Korniychuk G, Knirsch M, Engel J . Regulation of KCNQ4 potassium channel prepulse dependence and current amplitude by SGK1 in Xenopus oocytes. Cell Physiol Biochem. 2005; 16(4-6):255-62. DOI: 10.1159/000089851. View

Bentzen B, Schmitt N, Calloe K, Brown W, Grunnet M, Olesen S . The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006; 51(6):1068-77. DOI: 10.1016/j.neuropharm.2006.07.001. View

Tatulian L, Delmas P, Abogadie F, Brown D . Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci. 2001; 21(15):5535-45. PMC: 6762632. View

10.

Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G . K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature. 1996; 384(6604):78-80. DOI: 10.1038/384078a0. View

11.

Lerche C, Scherer C, Seebohm G, Derst C, Wei A, Busch A . Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J Biol Chem. 2000; 275(29):22395-400. DOI: 10.1074/jbc.M002378200. View

12.

Robbins J . KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacol Ther. 2001; 90(1):1-19. DOI: 10.1016/s0163-7258(01)00116-4. View

13.

Jentsch T . Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci. 2001; 1(1):21-30. DOI: 10.1038/35036198. View

14.

Towart R, Linders J, Hermans A, Rohrbacher J, van der Linde H, Ercken M . Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?. J Pharmacol Toxicol Methods. 2009; 60(1):1-10. DOI: 10.1016/j.vascn.2009.04.197. View

15.

Li Y, Gamper N, Shapiro M . Single-channel analysis of KCNQ K+ channels reveals the mechanism of augmentation by a cysteine-modifying reagent. J Neurosci. 2004; 24(22):5079-90. PMC: 6729199. DOI: 10.1523/JNEUROSCI.0882-04.2004. View

16.

Wu Y, Boissard C, Chen J, Fitzpatrick W, Gao Q, Gribkoff V . (S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons. Bioorg Med Chem Lett. 2004; 14(8):1991-5. DOI: 10.1016/j.bmcl.2004.01.069. View

17.

Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D . Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2004; 67(4):1053-66. DOI: 10.1124/mol.104.007112. View

18.

Schroder R, Jespersen T, Christophersen P, Strobaek D, Jensen B, Olesen S . KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology. 2001; 40(7):888-98. DOI: 10.1016/s0028-3908(01)00029-6. View

19.

Wang H, Brown B, McKinnon D, Cohen I . Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000; 57(6):1218-23. View

20.

Selyanko A, Hadley J, Wood I, Abogadie F, Jentsch T, Brown D . Inhibition of KCNQ1-4 potassium channels expressed in mammalian cells via M1 muscarinic acetylcholine receptors. J Physiol. 2000; 522 Pt 3:349-55. PMC: 2269765. DOI: 10.1111/j.1469-7793.2000.t01-2-00349.x. View